New Diagnostic Imaging MBS Items
In the 2021-22, Federal Budget the Government announced that from 1 July 2022 two new MBS items will be introduced for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) study for patients with prostate cancer.
The items, 61563 & 61564, will allow for a PSMA PET study for the initial staging of intermediate to high-risk patients with prostate cancer and for the restaging of patients with recurrent prostate cancer.
The new items will assist patients with prostate cancer to receive the most appropriate treatment pathway.
For more information download the factsheet: New Diagnostic Imaging Medicare Benefits Schedule (MBS) items 61563 and 61564